ArticleFrontiers in neurology2026
Association of platelet-rich plasma combined with dorsal root ganglion-targeted pulsed radiofrequency with outcomes in subacute thoracic herpes zoster neuralgia: a retrospective cohort study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subacute herpes zoster neuralgia is a clinically important transitional stage before pain becomes fully established as persistent postherpetic neuralgia. Methods: In this single-center retrospective cohort study, patients with subacute thoracic herpes zoster neuralgia treated between January 2024 and December 2025 were identified from routine clinical records. Patients were classified according to the treatment received as PRP + PRF or PRF alone. The primary outcome was the Numerical Rating Scale (NRS) score at 3 months after treatment. Repeated NRS and Pittsburgh Sleep Quality Index (PSQI) measurements were analyzed longitudinally. Secondary outcomes included pregabalin requirement and persistent clinically meaningful zoster-related pain, defined as NRS > 3 at the 3-month post-treatment follow-up. Results: Seventy patients were analyzed, including 36 in the PRP + PRF group and 34 in the PRF group. At 3 months, the observed mean NRS score was lower in the PRP + PRF group than in the PRF group (1.39 ± 1.44 vs. 2.56 ± 1.02). In the prespecified ANCOVA adjusted for baseline NRS, PRP + PRF was associated with a lower 3-month NRS score than PRF alone (adjusted mean difference, -1.13; 95% confidence interval [CI], -1.71 to -0.54; Conclusion: In this retrospective cohort, PRP combined with DRG-targeted PRF was associated with faster early improvement in pain and sleep and with lower post-treatment pregabalin use than PRF alone. Further prospective studies are needed to confirm these findings and determine whether this approach influences progression to persistent pain and PHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.